Schrödinger Signs a $2.7B Agreement with BMS to Develop and Commercialize Therapies in Multiple Disease Areas
Shots:
- Schrödinger to receive $55M upfront and is eligible to receive $2.7B as preclinical- development- regulatory & commercial milestones along with royalties on sales of each product commercialized by BMS
- Schrödinger to grant BMS exclusive WW rights to develop & commercialize the development candidates emerges from the collaboration
- The collaboration will merge Schrödinger’s computational platform & drug discovery capabilities with BMS' expertise in development & commercialization to advance small molecule therapies targeting oncology- immunology & neurological disorders. The collaboration includes two of Schrödinger’s early-stage programs and additional undisclosed targets
Ref: BusinessWire | Image: BMS
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com